HUE033204T2 - Factor II alone or in combination with additional factor for the treatment of impaired haemostasis associated with diluted coagulopathy - Google Patents
Factor II alone or in combination with additional factor for the treatment of impaired haemostasis associated with diluted coagulopathy Download PDFInfo
- Publication number
- HUE033204T2 HUE033204T2 HUE11761051A HUE11761051A HUE033204T2 HU E033204 T2 HUE033204 T2 HU E033204T2 HU E11761051 A HUE11761051 A HU E11761051A HU E11761051 A HUE11761051 A HU E11761051A HU E033204 T2 HUE033204 T2 HU E033204T2
- Authority
- HU
- Hungary
- Prior art keywords
- obb
- fii
- fibrinogen
- blood
- fviia
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title description 68
- 206010060906 Dilutional coagulopathy Diseases 0.000 title description 26
- 230000023597 hemostasis Effects 0.000 title description 24
- 230000001771 impaired effect Effects 0.000 title description 13
- 102000008946 Fibrinogen Human genes 0.000 claims description 127
- 108010049003 Fibrinogen Proteins 0.000 claims description 127
- 229940012952 fibrinogen Drugs 0.000 claims description 127
- 210000004369 blood Anatomy 0.000 claims description 93
- 239000008280 blood Substances 0.000 claims description 93
- 241000124008 Mammalia Species 0.000 claims description 13
- 230000004083 survival effect Effects 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims 2
- 241001482108 Alosa pseudoharengus Species 0.000 claims 1
- 240000007182 Ochroma pyramidale Species 0.000 claims 1
- 206010061592 cardiac fibrillation Diseases 0.000 claims 1
- 206010016531 fetishism Diseases 0.000 claims 1
- 230000002600 fibrillogenic effect Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 239000011800 void material Substances 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 56
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 56
- 239000003114 blood coagulation factor Substances 0.000 description 56
- 230000015271 coagulation Effects 0.000 description 53
- 238000005345 coagulation Methods 0.000 description 53
- 108090000190 Thrombin Proteins 0.000 description 42
- 206010053567 Coagulopathies Diseases 0.000 description 41
- 229960004072 thrombin Drugs 0.000 description 41
- 208000032843 Hemorrhage Diseases 0.000 description 33
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 32
- 230000035602 clotting Effects 0.000 description 29
- 238000000034 method Methods 0.000 description 29
- 229940030225 antihemorrhagics Drugs 0.000 description 28
- 230000000694 effects Effects 0.000 description 24
- 230000000740 bleeding effect Effects 0.000 description 23
- 208000034158 bleeding Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 238000010790 dilution Methods 0.000 description 20
- 239000012895 dilution Substances 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 18
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 17
- 230000000025 haemostatic effect Effects 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 108010073385 Fibrin Proteins 0.000 description 15
- 102000009123 Fibrin Human genes 0.000 description 15
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 229950003499 fibrin Drugs 0.000 description 15
- 108010094028 Prothrombin Proteins 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 206010059484 Haemodilution Diseases 0.000 description 11
- 102100027378 Prothrombin Human genes 0.000 description 11
- 229940039716 prothrombin Drugs 0.000 description 11
- 230000008733 trauma Effects 0.000 description 11
- 241001535291 Analges Species 0.000 description 10
- 108010000499 Thromboplastin Proteins 0.000 description 10
- 102000002262 Thromboplastin Human genes 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000009469 supplementation Effects 0.000 description 10
- 206010067125 Liver injury Diseases 0.000 description 9
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 231100000753 hepatic injury Toxicity 0.000 description 9
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 8
- 239000000535 fibrinogen concentrate Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000282887 Suidae Species 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 208000015294 blood coagulation disease Diseases 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 208000031169 hemorrhagic disease Diseases 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000001647 drug administration Methods 0.000 description 6
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 6
- -1 FXIa Proteins 0.000 description 5
- 238000001949 anaesthesia Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229940099990 ogen Drugs 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108010013773 recombinant FVIIa Proteins 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000004023 fresh frozen plasma Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 229940112216 novoseven Drugs 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102100026735 Coagulation factor VIII Human genes 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 108010071289 Factor XIII Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940012444 factor xiii Drugs 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000035761 normovolemia Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 239000003154 D dimer Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 2
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 239000012891 Ringer solution Substances 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 108010052295 fibrin fragment D Proteins 0.000 description 2
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000013169 thromboelastometry Methods 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229940075601 voluven Drugs 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- ZCBJDQBSLZREAA-UHFFFAOYSA-N Bisoxatin acetate Chemical compound C1=CC(OC(=O)C)=CC=C1C1(C=2C=CC(OC(C)=O)=CC=2)C(=O)NC2=CC=CC=C2O1 ZCBJDQBSLZREAA-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108010082995 Dermatophagoides farinae antigen f 2 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000036064 Surgical Blood Loss Diseases 0.000 description 1
- 241001080024 Telles Species 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 102000004210 Vitamin K Epoxide Reductases Human genes 0.000 description 1
- 108090000779 Vitamin K Epoxide Reductases Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000016804 acquired coagulation factor deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940070435 anti-inhibitor coagulant complex Drugs 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229950003616 azaperone Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 108090001015 cancer procoagulant Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 208000014763 coagulation protein disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000000173 fibrin polymerisation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- IHEHEFLXQFOQJO-UHFFFAOYSA-N piritramide Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 IHEHEFLXQFOQJO-UHFFFAOYSA-N 0.000 description 1
- 229960001286 piritramide Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 108010014806 prothrombinase complex Proteins 0.000 description 1
- 229940068953 recombinant fviia Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000012032 thrombin generation assay Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39022410P | 2010-10-06 | 2010-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE033204T2 true HUE033204T2 (en) | 2017-11-28 |
Family
ID=44677879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE11761051A HUE033204T2 (en) | 2010-10-06 | 2011-09-19 | Factor II alone or in combination with additional factor for the treatment of impaired haemostasis associated with diluted coagulopathy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9433664B2 (enExample) |
| EP (1) | EP2624859B1 (enExample) |
| JP (1) | JP6000259B2 (enExample) |
| KR (1) | KR20130136988A (enExample) |
| CN (1) | CN103221061A (enExample) |
| AU (1) | AU2011313505B2 (enExample) |
| BR (1) | BR112013008034A2 (enExample) |
| CA (1) | CA2812888A1 (enExample) |
| DK (1) | DK2624859T3 (enExample) |
| ES (1) | ES2625153T3 (enExample) |
| HU (1) | HUE033204T2 (enExample) |
| MX (1) | MX343784B (enExample) |
| PL (1) | PL2624859T3 (enExample) |
| RU (1) | RU2606155C2 (enExample) |
| SG (2) | SG10201508159SA (enExample) |
| WO (1) | WO2012045569A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12171463B2 (en) | 2008-10-03 | 2024-12-24 | Femasys Inc. | Contrast agent generation and injection system for sonographic imaging |
| SG10201508159SA (en) | 2010-10-06 | 2015-10-29 | Medimmune Ltd | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders |
| IL230150A0 (en) * | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One-component fibrin glue containing zymogens |
| JP7227905B2 (ja) | 2017-02-09 | 2023-02-22 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血の処置または予防における使用のための血液凝固因子代替製品 |
| CN116059431A (zh) * | 2021-10-29 | 2023-05-05 | 丁琴琴 | 一种含凝血因子的双层止血敷料及其制备方法 |
| WO2023220412A1 (en) * | 2022-05-13 | 2023-11-16 | Cedars-Sinai Medical Center | Hemostatic monitor |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3165600D1 (en) | 1980-01-28 | 1984-09-27 | Baxter Travenol Lab | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions |
| US4501731A (en) | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
| DE4430204A1 (de) | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung |
| HUP9700603A3 (en) | 1996-03-20 | 2001-08-28 | Baxter Ag | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| AT409334B (de) | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
| US7094428B2 (en) | 2000-06-16 | 2006-08-22 | The University Of Medicine And Dentistry Of New Jersey | Hemostatic compositions, devices and methods |
| US6825323B2 (en) | 2001-01-10 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
| ATE386538T1 (de) | 2001-02-05 | 2008-03-15 | Novo Nordisk Healthcare Ag | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden |
| US20060025336A1 (en) | 2001-07-16 | 2006-02-02 | Novo Nordisk A/S | Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides |
| AU2002354846B2 (en) | 2001-07-20 | 2007-08-02 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides |
| US20040101546A1 (en) * | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
| EP1587424A4 (en) | 2002-12-31 | 2012-01-25 | Marinepolymer Tech Inc | Bleeding Compounds and their uses |
| GB0324044D0 (en) | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| EP1748781B1 (en) | 2004-05-27 | 2012-12-19 | Baxter International Inc. | Methods for treating bleeding disorders using sulfated polysaccharides |
| EP1893230A2 (en) | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| MX2008006313A (es) | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| CA2644926A1 (en) * | 2006-03-06 | 2007-09-13 | Humagene, Inc. | A method for the preparation of recombinant human thrombin and fibrinogen |
| US20080014251A1 (en) | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
| WO2008051513A2 (en) | 2006-10-23 | 2008-05-02 | Allan Pronovost | Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding |
| EP1935429A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates |
| US20080267940A1 (en) | 2007-03-30 | 2008-10-30 | Mohammed Syed F | Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue |
| NZ579985A (en) | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| US8852558B2 (en) | 2008-03-11 | 2014-10-07 | Materials Modification, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst |
| EP2337793A4 (en) | 2008-10-08 | 2013-04-10 | Thrombodyne Inc | METHOD FOR PRODUCING CONCENTRATED FIBRINOGEN AND PLAIN-CONTAINING COMPOSITIONS |
| SG10201508159SA (en) | 2010-10-06 | 2015-10-29 | Medimmune Ltd | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders |
-
2011
- 2011-09-19 SG SG10201508159SA patent/SG10201508159SA/en unknown
- 2011-09-19 SG SG2013021498A patent/SG188639A1/en unknown
- 2011-09-19 ES ES11761051.9T patent/ES2625153T3/es active Active
- 2011-09-19 BR BR112013008034A patent/BR112013008034A2/pt not_active IP Right Cessation
- 2011-09-19 EP EP11761051.9A patent/EP2624859B1/en not_active Revoked
- 2011-09-19 JP JP2013532104A patent/JP6000259B2/ja not_active Expired - Fee Related
- 2011-09-19 KR KR1020137008520A patent/KR20130136988A/ko not_active Ceased
- 2011-09-19 RU RU2013120033A patent/RU2606155C2/ru not_active IP Right Cessation
- 2011-09-19 PL PL11761051T patent/PL2624859T3/pl unknown
- 2011-09-19 DK DK11761051.9T patent/DK2624859T3/en active
- 2011-09-19 US US13/877,854 patent/US9433664B2/en not_active Expired - Fee Related
- 2011-09-19 CA CA2812888A patent/CA2812888A1/en not_active Abandoned
- 2011-09-19 HU HUE11761051A patent/HUE033204T2/en unknown
- 2011-09-19 WO PCT/EP2011/066241 patent/WO2012045569A1/en not_active Ceased
- 2011-09-19 CN CN2011800479754A patent/CN103221061A/zh active Pending
- 2011-09-19 AU AU2011313505A patent/AU2011313505B2/en not_active Ceased
- 2011-09-19 MX MX2013003715A patent/MX343784B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011313505A1 (en) | 2013-04-11 |
| DK2624859T3 (en) | 2017-06-06 |
| SG10201508159SA (en) | 2015-10-29 |
| WO2012045569A1 (en) | 2012-04-12 |
| CN103221061A (zh) | 2013-07-24 |
| AU2011313505B2 (en) | 2015-09-17 |
| US9433664B2 (en) | 2016-09-06 |
| MX2013003715A (es) | 2013-09-26 |
| JP2013538863A (ja) | 2013-10-17 |
| WO2012045569A9 (en) | 2016-01-07 |
| JP6000259B2 (ja) | 2016-09-28 |
| EP2624859B1 (en) | 2017-03-01 |
| RU2013120033A (ru) | 2014-11-20 |
| ES2625153T3 (es) | 2017-07-18 |
| US20130280236A1 (en) | 2013-10-24 |
| EP2624859A1 (en) | 2013-08-14 |
| SG188639A1 (en) | 2013-05-31 |
| KR20130136988A (ko) | 2013-12-13 |
| CA2812888A1 (en) | 2012-04-12 |
| MX343784B (es) | 2016-11-23 |
| RU2606155C2 (ru) | 2017-01-10 |
| PL2624859T3 (pl) | 2017-09-29 |
| BR112013008034A2 (pt) | 2016-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moore et al. | Does tranexamic acid improve clot strength in severely injured patients who have elevated fibrin degradation products and low fibrinolytic activity, measured by thrombelastography? | |
| Lambourne et al. | Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate | |
| ERIKSEN et al. | Mechanisms of hydroxyethyl starch‐induced dilutional coagulopathy | |
| Sane et al. | Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management | |
| Fries et al. | Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy—a porcine model | |
| Dickneite et al. | Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P) | |
| Schulman | Pharmacologic tools to reduce bleeding in surgery | |
| JPS58500994A (ja) | 止血用医薬組成物 | |
| Chee et al. | Management of bleeding in vascular surgery | |
| Honickel et al. | Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model | |
| BG64542B1 (bg) | ФАРМАЦЕВТИЧЕН СЪСТАВ, ВКЛЮЧВАЩ СЪЕДИНЕНИЕ, ПРИТЕЖАВАЩО АНТИ- Хa АКТИВНОСТ И СЪЕДИНЕНИЕ-АНТАГОНИСТ НА АГРЕГИРАНЕТО НА ТРОМБОЦИТИТЕ | |
| Premkumar et al. | Current concepts in coagulation profile in cirrhosis and acute‐on‐chronic liver failure | |
| EP2624859B1 (en) | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy | |
| Honickel et al. | Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model | |
| Woessner et al. | Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke: Results of a randomized, placebo-controlled, double-blind study | |
| Solomon et al. | Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery | |
| US20100279939A1 (en) | Recombinant human fibrinogen for treatment of bleeding in trauma and platelet disorders | |
| KR20110043654A (ko) | 폰 빌레브란트 인자 또는 제ⅷ 인자 및 혈소판의 억제제에 의하여 유도된 응고장애 치료용 폰 빌레브란트 인자 | |
| Rogers et al. | Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis | |
| Marin et al. | Dysfibrinogenemia: discrepant results following infusion of purified fibrinogen | |
| HK1188391B (en) | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy | |
| HK1188391A (en) | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy | |
| Favaloro et al. | Editorial compilation X | |
| JP2012519674A (ja) | フィブリノーゲンの新規な使用 | |
| STH | Editorial Compilation XI |